As of 6 Nov 2026, Viyash Scientific trades at 56.1× trailing earnings, above the industry P/E of 28.7×, and the shares are 23% below their 52-week high. Its ROCE of 11% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales grew 33% a year over 3 years. Debt is 0.16× equity. It is a small-cap company with a market cap of ₹10,133 Cr, ranked 33rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 6.3% over the past year.
- ₹231.20
- ₹232.40
- ₹225.70
- ₹232.82
- 10.5 L
Health check
- ReturnsBehind
+6.3% over a year, better than 1 of 7 peers.
- Price tagPricier
P/E 56.1 vs industry 28.7.
- GrowthStrong
Sales +33.3% a year over 3 years.
- ProfitabilityWeak
ROCE 11.2% vs peer median 17.9%.
- Balance sheetSolid
Debt 0.16× equity, interest covered 6.5×, Piotroski 8 of 9.
- Red flags3 to check
Return on equity is low at 6.6%.
Small cap
Moves with the market
Key metrics
- Market cap
- ₹10,133 Cr
- Small cap
- P/E
- 56.1
- Industry 28.7
- Price to book
- 3.44
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- 6.6%
- Peers 14.7%
- ROCE
- 11.2%
- Peers 17.9%
- Debt to equity
- 0.16
- Debt ₹490 Cr
- EPS (TTM)
- ₹4.09
- Face value ₹2
- OPM (TTM)
- 19.1%
- Net margin 5.9%
- Sales growth
- +19.5%
- Latest quarter vs a year ago
- Profit growth
- +107.1%
- Latest quarter vs a year ago
- Price to sales
- 2.83
- EV/EBITDA 15.3
Strengths and risks
Strengths
- Quarterly profit up 107.1% on a year ago.
- Quarterly sales up 19.5% on a year ago.
- Positive operating cash flow in each of the last 4 years.
Risks to check
- Return on equity is low at 6.6%.
- P/E of 56.1 against an industry P/E of 28.7.
- Promoter stake down from 61.4% to 49.2%.
About Viyash Scientific
Viyash Scientific Limited operates as a veterinary pharmaceutical Company in India, the United States, Spain, and internationally. The company provides active pharmaceutical ingredients, finished dosage formulations, analytical services, and VET formulation services for cattle and poultry. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and…
- Headquarters
- Hyderabad
- Employees
- 2,900
- Sector
- Healthcare
- ISIN
- INE807F01027
- Website
- viyash.com
Price range
- Avg volume (3M)
- 47.8 L
- 1-year return
- plus 6.3%
- From 52-week high
- minus 23.0%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| VIYASHViyash Scientific | 229.48 | minus 1.43% | 10,133 | 56.1 | 3.44 | 11.2% | 6.6% | 19.1% | 33.3% | – | 0.00% | plus 6.3% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 792 | 424 | 858 | 920 | 946 | |
| 677 | 368 | 682 | 732 | 767 | |
| 115 | 56.4 | 176 | 188 | 180 | |
| 14.5% | 13.3% | 20.5% | 20.5% | 19.0% | |
| 6.8 | 2.2 | 14 | 15.9 | 8.3 | |
| 20.4 | 13.5 | 16.8 | 14.5 | 12.5 | |
| 55.6 | 15.5 | 58.5 | 60.4 | 61.8 | |
| 2.5 | −2.5 | −41.8 | −4.2 | −1.4 | |
| 48.3 | 27.2 | 73.1 | 125 | 112 | |
| 23.8% | 27.8% | 33.6% | 47.0% | 29.5% | |
| 31.8 | 14.7 | 38.4 | 52.1 | 65.9 | |
| 0.73 | 0.58 | 0.87 | 1.17 | 1.47 |
Profit & loss
- Sales CAGR 3Y
- +33.3%
- ROE
- 6.6%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 1,418 | 1,366 | 2,963 | 3,357 | |
| – | minus 3.7% | +116.9% | +13.3% | |
| 1,362 | 1,313 | 2,632 | 2,673 | |
| 56 | 53.3 | 331 | 684 | |
| 3.9% | 3.9% | 11.2% | 20.4% | |
| −48.8 | 19.9 | 67.8 | 0.5 | |
| 29.7 | 46.4 | 79.3 | 63.8 | |
| 55.7 | 61.5 | 239 | 234 | |
| −59.4 | −19.9 | −67.8 | −38.3 | |
| −138 | −54.6 | 13.2 | 349 | |
| 11.4% | 45.8% | −19.6% | 35.6% | |
| −121 | −35.9 | 23.2 | 177 | |
| -4.88 | -1.44 | 0.53 | 4.01 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 49.9 | 49.9 | 50.1 | 87.4 | |
| 649 | 607 | 2,382 | 2,824 | |
| 444 | 488 | 654 | 490 | |
| 387 | 396 | 1,046 | 1,228 | |
| 1,529 | 1,540 | 4,132 | 4,628 | |
| 352 | 311 | 1,148 | 1,208 | |
| 51.6 | 11.3 | 48.6 | 70.5 | |
| 7.1 | 7.5 | 4.5 | 6.7 | |
| 41.6 | 68.8 | 149 | 270 | |
| 1,076 | 1,141 | 2,782 | 3,073 | |
| 1,529 | 1,540 | 4,132 | 4,628 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 16.8 | 30.6 | 345 | 323 | |
| −65 | −5.9 | −447 | −84.1 | |
| 32.2 | −1.4 | 87 | −123 | |
| −15.9 | 23.2 | −15.4 | 115 | |
| −86.2 | −30.8 | −108 | −135 | |
| −69.4 | −0.2 | 237 | 188 |
Shareholding pattern
- Promoters49.24%
- Public50.66%
- Employee trusts0.09%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 49.24% | 50.66% | minus 12.07 | |
| 30 Jun 2026 | 61.31% | 38.60% | 0.00 | |
| 31 Mar 2026 | 61.31% | 38.59% | minus 0.10 | |
| 31 Dec 2025 | 61.41% | 38.49% | minus 0.02 | |
| 16 Dec 2025 | 61.43% | 38.48% | – |
Major shareholders
Filings & events
News
No recent news coverage found.